Loading…
Loading…
Compass Financial Management LLC acquired a new stake in Gilead Sciences, Inc. (NASDAQ: GILD) in the undefined quarter, according to its most recent Form 13F filing with the SEC. The institutional investor acquired 5,244 shares of the biopharmaceutical company's stock, valued at approximately $671,000. Other institutional investors and hedge funds also recently added
Gilead is best known for its dominant HIV franchise. But the company has been actively diversifying via acquisitions.
Gilead's quarterly dividend keeps growing and its HIV cash machine runs hot, but the whole enterprise depends on a single blockbuster drug with a patent expiration already penciled onto a calendar a decade out.
Gilead (GILD) reported earnings 30 days ago. What's next for the stock?
GILD's FDA approval of Bixlenvo expands its HIV portfolio with a first-of-its-kind single-tablet option for underserved patients.
Gilead (GILD) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?
Archer Investment Corp acquired a new position in shares of Gilead Sciences, Inc. (NASDAQ: GILD) in the undefined quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 7,578 shares of the biopharmaceutical company's stock, valued at approximately $957,000. A number of other hedge funds